UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) March 11, 2002
Commission File Number 001-10304
AMEXDRUG CORPORATION
--------------------
(Exact Name of Registrant as Specified in its Charter)
Nevada 95-2251025
------ ----------
(State or other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)
396 South Doheny Drive, Suite 326
---------------------------------
Beverly Hills, California
-------------------------
(Address of principal executive offices)
90211
------
(Zip Code)
(310) 855-0475
--------------
(Registrant's Executive Office Telephone Number)
1
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
(a) On March 11, 2002, Amexdrug Corporation (the "Company") engaged
Hansen, Barnett & Maxwell ("HB&M") as its independent accountant. The
decision to engage HB&M as the Company's independent accountant was
recommended by the Company's Chief Executive Officer and approved by
the Company's Board of Directors.
(b) In a report dated July 25, 2001, Andersen Andersen & Strong, L.C.,
reported on the Company's financial statements as of June 30, 2001,
2000 and 1999, and the related statements of operations, stockholders'
equity and cash flows for the years then ended, and for the period
from inception through June 30, 2001. Such report did not contain an
adverse opinion or disclaimer of opinion, nor was such report
qualified or modified as to uncertainty, audit scope, or accounting
principles. Andersen Andersen & Strong, L.C., understands that they
were dismissed as the Company's independent accountants effective
March 11, 2002. The decision to dismiss Andersen Andersen & Strong,
L.C., was made by the Company's Chief Executive Officer and neither
recommended or approved by the Company's Board of Directors.
Thereafter, the Company engaged HB&M as its independent accountants on
March 11, 2002.
(c) During the two years ended June 30, 2001 and 2000, and the subsequent
interim period to March 11, 2002, preceding the decision to engage
independent accountants, neither the Company nor anyone on its behalf
consulted HB&M regarding either the application of accounting
principles to a specified transactions, either completed or proposed,
or the type of audit opinion that might be rendered on the Company's
financial statements, nor has HB&M provided to the Company a written
report or oral advice regarding such principles or audit opinion.
(d) During the two years ended June 30, 2001 and 2000, and for the period
from June 30, 2001 to March 11, 2002, the date of dismissal, there
were: (i) no disagreements between the Company and Andersen Andersen &
Strong, L.C., on any matter or accounting principles or practice,
financial statement disclosure, or auditing scope or procedure, which
disagreements if not resolved to the satisfaction of Andersen Andersen
& Strong, L.C., would have caused it to make reference thereto in its
report; and (ii) no reportable events as defined in paragraph
304(a)(1)(iv) of Regulation S-B.
Andersen Andersen & Strong, L.C., has provided the Company with a letter
pursuant to Rule 304 of Regulation S-B.
2
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
Exhibits. The following exhibits are included as part of this report:
Exhibit SEC
Number Ref. Title of Document Location
------ ---- ----------------- --------
16.01 16 Letter regarding change in Attached
Certifying Accountant
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Current Report on Form 8-K to be signed on
its behalf by the undersigned hereunto duly authorized.
AMEXDRUG CORPORATION
Date: March 14, 2002 By /s/ Jack Amin
------------------------
President, Treasurer
3
EXHIBIT 16.01
Letter re change in Certifying Accountant
ANDERSEN ANDERSEN & STRONG, L.C.
- --------------------------------
Certified Public Accountants and Business Consultants
Member SEC Practice Section of the AICPA 941 East 3300 South, Suite 202
Salt Lake City, Utah 84106
Telephone 801 486-0096
Fax 801 486-0098
March 13, 2002
Securities & Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Gentlemen:
I have read the disclosure regarding changes in registrant's certifying
accountant as reported on Form 8-K for Amexdrug Corporation dated March 13,
2002. I am in agreement with the statements contained therein so far as they
relate to Andersen Andersen & Strong, L.C. I have no basis to agree or disagree
with other statements of the registrant contained therein.
/s/ Andersen Andersen & Strong, L.C.
- ------------------------------------
Andersen Andersen & Strong, L.C.